Bayer, ArcherDX to Develop NGS-Based Companion Diagnostic for Vitrakvi
May 14 2020 - 8:00AM
Dow Jones News
By Mauro Orru
Bayer AG said Thursday that it would develop a next-generation
sequencing-based companion diagnostic for Vitrakvi along with
Colorado-based biotechnology company ArcherDX.
The German pharmaceutical and chemical company didn't disclose
financial details, but said its partnership with ArcherDX is aimed
at expanding patient access to genomic testing.
Next-generation sequencing-based companion diagnostic testing
seeks to release molecular information from patients' tumor genomes
to subsequently guide treatment decisions for cancer therapies,
Bayer said.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
May 14, 2020 07:45 ET (11:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Sep 2023 to Sep 2024